Sage Journals: Discover world-class research

Abstract

Objective

To systematically review and summarize the available literature regarding the effectiveness and safety of biologics in the treatment of juvenile-onset systemic lupus erythematosus.

Methods

PubMed was systematically searched for relevant literature (2012–2017 inclusive) using the following criteria: (1) patients diagnosed with juvenile-onset systemic lupus erythematosus (≤18 years at diagnosis); (2) treatment with any biological agent; and (3) outcome measures assessing effectiveness and safety. Systematic literature reviews, meta-analyses, randomized controlled trials, cohort studies, case control studies, cross sectional surveys and case-series with ≥3 patients were included. Independent extraction of articles by two authors using predefined criteria was performed. The quality of each study was assessed using CASP tools and Oxford CEBM Levels of Evidence.

Results

Nine articles met inclusion criteria: six cohort studies, two case series and one pilot study, totalling 230 patients. All but one article reported the effects of rituximab, the other those of belimumab. Overall, patients had active disease refractory to standard of care regimens using corticosteroids and immunosuppressants. Available evidence for rituximab demonstrated improvements in disease activity, complement levels and anti-dsDNA titres accompanying a steroid-sparing effect.

Conclusion

Rituximab can be considered an effective treatment in juvenile-onset systemic lupus erythematosus patients with severe disease manifestations and/or refractory disease. Based on current evidence, use of belimumab in juvenile-onset systemic lupus erythematosus patients cannot be recommended. The long-term safety of these biological agents remains uncertain. Further prospective studies, ideally robust randomized controlled trials, are urgently needed to obtain more accurate data on the effectiveness and long-term safety of rituximab, belimumab and other biologics in juvenile-onset systemic lupus erythematosus.

Keywords

JSLE biologics rituximab belimumab safety effectiveness paediatric rheumatology

Get full access to this article

View all access options for this article.

References

Thorbinson

Oni

Smith

et al.

Pharmacological management of childhood-onset systemic lupus erythematosus. Paediatr Drugs 2016; 18: 181–195.

Midgley

Watson

Beresford

. New insights into the pathogenesis and management of lupus in children. Arch Dis Child 2014; 99: 563–567.

Habibi

Saleem

Ramanan

. Juvenile systemic lupus erythematosus: review of clinical features and management. Indian Pediatr 2011; 48: 879–887.

Sinha

Raut

. Pediatric lupus nephritis: Management update. World J Nephrol 2014; 3: 16–23.

Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus 2016; 25: 1542–1550.

Watson

Leone

Pilkington

et al.

Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64: 2356–2365.

Couture

Silverman

. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol 2016; 28: 488–496.

Groot

de Graeff

Avcin

et al.

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017; 76: 1788–1796.

Duxbury

Combescure

Chizzolini

. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2015; 22: 1489–1503.

10.

Cobo-Ibanez

Loza-Santamaria

Pego-Reigosa

et al.

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2014; 44: 175–185.

11.

Kone-Paut I, Piram M, Guillaume S, et al. Lupus in adolescence. Lupus 2007; 16: 606–612.

12.

Thamer

Hernan

Zhang

et al.

Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36: 560–564.

13.

Levy

Kamphuis

. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am 2012; 59: 345–364.

14.

Oktem

Guzel

Aksoy

et al.

Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. Obstet Gynecol Surv 2015; 70: 196–210.

15.

Bernal

Zamora

Navarra

. Biologic therapies in systemic lupus erythematosus. Int J Rheum Dis 2015; 18: 146–153.

16.

van Vollenhoven

Parodis

Levitsky

. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 2013; 27: 341–349.

17.

Cancro

D'Cruz

Khamashta

. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119: 1066–1073.

18.

Tsokos

Costa Reis

et al.

New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016; 12: 716–730.

19.

Mahajan

Herrmann

Munoz

. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol 2016; 7: 35.

20.

Stohl

Metyas

Tan

S-M

et al.

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475–3486.

21.

Trachana

Koutsonikoli

Farmaki

et al.

Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013; 33: 809–813.

22.

Ramos-Casals

Brito-Zeron

Munoz

et al.

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008; 87: 345–364.

23.

Leone

Sciascia

Kamal

et al.

Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 2015; 11: 109–116.

24.

Watson

Beresford

Maynes

et al.

The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015; 24: 10–17.

25.

Critical Appraisal Skills Programme. CASP Checklists, https://casp-uk.net/casp-tools-checklists (2018, accessed 8 December 2016).

26.

Centre for Evidence-Based Medicine. Oxford Centre for Evidence-based Medicine – Levels of Evidence, www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 (2009, accessed 8 December 2016).

27.

Sterne

Hernan

Reeves

et al.

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.

28.

Tambralli

Beukelman

Cron

et al.

Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol 2015; 42: 541–546.

29.

Olfat

Silverman

Levy

. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus 2015; 24: 966–972.

30.

Dale

Brilot

Duffy

et al.

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83: 142–150.

31.

Ale'ed

Alsonbul

Al-Mayouf

. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014; 34: 529–533.

32.

Hui-Yuen

Reddy

Taylor

et al.

Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 2015; 42: 2288–2295.

33.

Reis

Aguiar

Brito

. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases. Acta Reumatol Port 2016; 41: 45–55.

34.

Lehman

Singh

Ramanathan

et al.

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12: 3.

35.

Touma

Gladman

Ibanez

et al.

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011; 38: 2395–2399.

36.

Khraishi M, Aslanov R, Dixit S, et al. The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study – ACR Abstract Supplement. Arthritis Rheum 2014; 66: S311–312.

37.

Brunner

Silverman

Bombardier

et al.

European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003; 49: 335–341.

38.

Marks

Pilkington

Woo

et al.

The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. Rheumatology 2004; 43: 1186–1189.

39.

Harrison

McArthur

Quinn

. Assessment scales in stroke: clinimetric and clinical considerations. Clin Interv Aging 2013; 8: 201–211.

40.

Papadimitraki

Isenberg

. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 2009; 5: 391–403.

41.

Sthoeger

Lorber

Tal

et al.

Anti-BLyS treatment of 36 Israeli systemic lupus erythematosus patients. Isr Med Assoc J 2017; 19: 44–48.

42.

Merrill

Neuwelt

Wallace

et al.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222–233.

43.

Rovin

Furie

Latinis

et al.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with rituximab study. Arthritis Rheum 2012; 64: 1215–1226.

44.

Mosak

Furie

. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. Lupus 2013; 22: 361–371.

45.

Hui-Yuen

Nguyen

Askanase

. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus 2016; 25: 1086–1096.

46.

van Vollenhoven

Petri

Cervera

et al.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71: 1343–1349.

47.

Navarra

Guzman

Gallacher

et al.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731.

48.

Furie

Petri

Zamani

et al.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.

49.

Morbach

Girschick

. [B-cell targeted therapy for children and adolescents with rheumatic diseases]. Z Rheumatol 2013; 72: 347–353.

50.

Grampp

Ramanan

. Managing unexpected events in the manufacturing of biologic medicines. BioDrugs 2013; 27: 305–316.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.88 MB

The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review

Abstract

Objective

Methods

Results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material